The CNS Market Outlook to 2016

Introduction

This report provides comprehensive coverage of the global CNS market, incorporating disease overview, epidemiological analyses of the major indications, and market dynamics. Resistors and drivers are examined along with the most promising areas of growth. Current leading CNS brands are assessed and five of the market’s leading players are profiled.

Features and benefits

* Assess the forecast epidemiology and development of the CNS disorders across the 7MM.
* Analyze the dynamics of the global CNS market and understand the impact of key R&D events, market trends, and issues.
* Gain up-to-date competitive intelligence and understand the major issues affecting key pharmaceutical marketers and product development.
* Predict revenues for major currently marketed and pipeline CNS products over from 2010 to 2016.
* Develop strategies for success in the future CNS market.

Highlights

Antipsychotics were the largest CNS drug class with $24.2bn sales, a 33.9% share of the market in 2010. Patent expirations of key brands Seroquel and Zyprexa will form the main resistors to segmental growth through 2016.
Imminent patent expiries for major brands have resulted in companies investigating new indications and re-formulation strategies to extend patents and safeguard revenue streams. Companies have also begun to manufacture and market generic versions of their products.
Of the indications in the CNS category, Alzheimer's disease (AD) represents the main area of R&D interest for pharmaceutical companies, with an estimated 288 compounds in various stages of development.

Your key questions answered

* What are the drivers and resistors of the CNS market worldwide?
* What market and pipeline developments are shaping the strategies of leading pharmaceutical companies in the CNS market?
* What is the forecast commercial potential of the most promising compounds in clinical development?
* Who were the leading players in the global CNS market in 2010?
* How have recent launches from companies such as Allergan, P&G, GSK, Eisai, and Novartis performed?
[Studien Infos ausblenden]

Executive Summary
Overview and epidemiology of CNS disorders
Industry structure and market dynamics
Pipeline analysis
Competitive landscape
About the author
Disclaimer
Overview and epidemiology of CNS disorders
Summary
Introduction
Major depressive disorder (MDD)
Epilepsy
Schizophrenia
Alzheimer's disease
Parkinson's disease
Migraine
Insomnia
Attention-deficit hyperactivity disorder
Industry structure and market dynamics
Summary
Introduction
Global CNS market
Key events
Market drivers
Market challenges
Leading CNS brands
Market analysis by drug class
Antipsychotics
Antidepressants
Anti-epileptics
Alzheimer’s disease
Psychostimulants
Parkinson’s disease
Hypnotic/sedatives
Anti-migraine drugs
Genericization in the CNS market
Global CNS sales forecast
Pipeline analysis
Summary
Introduction
Key trends in R&D
Disease modifying therapies hold promise in Alzheimer’s disease
Anti-migraine market sees newer therapies after many years
Novel drugs with differentiated clinical profiles represent a sizeable market opportunity
SSRI generics and branded SNRIs are changing the depression landscape
Label expansions of antidepressants provide a significant opportunity for growth
Combination products hold potential in CNS market
CNS disorders pipeline
Key products under major CNS disorders
Leading drugs in development
Silenor (doxepin hydrochloride) – P&G/Somaxon Pharmaceuticals
Botox (onabotulinumtoxin-A) – Allergan
Potiga/Trobalt (retigabine/ezogabine) – GSK/Valeant Pharmaceuticals
Stedesa/Zebinix (eslicarbazepine acetate) – Sepracor/Eisai/Bial Group
Valdoxan/Thymanax/AGO178 (agomelatine) – Novartis and Servier
Latuda (lurasidone) – Dainippon Sumitomo
Levadex (dihydroergotamine mesylate) – MAP Pharmaceuticals/Allergan
Bapineuzumab (AAB-001) – Elan/J&J/Pfizer
Solanezumab (LY2062430) – Eli Lilly
Telcagepant (MK-0974) – Merck
RG1678/RO4917838 – Roche/Chugai
TC-5214 (S-mecamylamine) – AstraZeneca/Targacept
LY2216684/NERI (edivoxetine) – Eli Lilly
MK-4305 – Merck & Co.
IPX066 (Carbidopa/levodopa) – GSK and Impax
Pipeline forecast of leading drugs in development
Competitive landscape
Summary
Introduction
Eli Lilly
Overview
Financial performance
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Pfizer
Overview
Financial performance
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
AstraZeneca
Overview
Financial performance
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Johnson & Johnson
Overview
Financial performance
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
GlaxoSmithKline
Overview
Financial performance
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Appendix
Scope
Methodology
Market size methodology
Epidemiology
Market forecast
Glossary/Abbreviations
Bibliography/References
Prevalence of MDD
Prevalence of epilepsy
Prevalence of schizophrenia
Prevalence of Alzheimer’s disease
Prevalence of Parkinson’s disease
Prevalence of migraine
Prevalence of insomnia
Prevalence of ADHD
Others
[Inhaltsverzeichnis ausblenden]